scholarly journals Misoprostol inhibits gastric mucosal release of endogenous prostaglandin E2 and thromboxane B2 in healthy volunteers.

Gut ◽  
1995 ◽  
Vol 36 (4) ◽  
pp. 511-515 ◽  
Author(s):  
A Mertz-Nielsen ◽  
O Eskerod ◽  
K Bukhave ◽  
J Rask-Madsen
Keyword(s):  
Prostaglandin E2 ◽  
Healthy Volunteers ◽  
Thromboxane B2 ◽  
Endogenous Prostaglandin

Bronchoprotective role for endogenous prostaglandin E2

The Lancet ◽  
1995 ◽  
Vol 345 (8947) ◽  
pp. 436-438 ◽  
Author(s):  
I.D. Pavord ◽  
A.E. Tattersfield
Keyword(s):  
Prostaglandin E2 ◽  
Endogenous Prostaglandin

Low-dose enteric-coated aspirin does not inhibit thromboxane B2 and prostaglandin E2: data-derived hypothesis formulation

2012 ◽  
Vol 2 (7) ◽  
pp. 747-752 ◽  
Author(s):  
Charles H Hennekens ◽  
Scott Hetzel ◽  
Michael Pfeffer ◽  
Ricky Schneider ◽  
Steven Borzak ◽  
...  
Keyword(s):  
Prostaglandin E2 ◽  
Low Dose ◽  
Thromboxane B2 ◽  
Enteric Coated Aspirin ◽  
Enteric Coated

scholarly journals Urinary thromboxane B2 and prostaglandin E2 in the hepatorenal syndrome: Evidence for increased vasoconstrictor and decreased vasodilator factors

1983 ◽  
Vol 84 (4) ◽  
pp. 697-703 ◽  
Author(s):  
Robert D. Zipser ◽  
George H. Radvan ◽  
Ian J. Kronborg ◽  
Robert Duke ◽  
Timothy E. Little
Keyword(s):  
Prostaglandin E2 ◽  
Hepatorenal Syndrome ◽  
Thromboxane B2

Model-based analysis of thromboxane B2 and prostaglandin E2 as biomarkers in the safety evaluation of naproxen

2014 ◽  
Vol 278 (3) ◽  
pp. 209-219 ◽  
Author(s):  
Tarjinder Sahota ◽  
Ian Sanderson ◽  
Meindert Danhof ◽  
Oscar Della Pasqua
Keyword(s):  
Prostaglandin E2 ◽  
Safety Evaluation ◽  
Thromboxane B2 ◽  
Model Based ◽  
Model Based Analysis

Tubular prostaglandin E2 production and its role in urinary hypotonicity after release of ureteral occlusion in the rat

1987 ◽  
Vol 73 (4) ◽  
pp. 395-399 ◽  
Author(s):  
Shozo Torikai
Keyword(s):  
Prostaglandin E2 ◽  
Collecting Duct ◽  
Urine Osmolality ◽  
Urine Concentration ◽  
Pge2 Production ◽  
Endogenous Prostaglandin ◽  
Collecting Ducts ◽  
Ureteral Occlusion

1. In order to explore the involvement of endogenous prostaglandin E2 (PGE2) in the urine concentration defect after ureteral occlusion, PGE2 production by isolated collecting ducts in vitro and effects of indomethacin on urine osmolality in vivo were examined. 2. Twenty-four hours ureter obstruction caused increased PGE2 production by the medullary collecting ducts, which was maintained at a high level on the day after release of obstruction (0.8 ± 0.2 pg/mm normal, 8.1 ± 0.9 pg/mm 24 h obstruction, and 6.6 ± 1.0 pg/mm post-obstruction, mean ± sem). An enhanced PGE2 production was also observed for papillary collecting duct on the day after release of 24 h ureteral occlusion (3.9 ± 0.5 pg/mm normal and 7.7 ± 1.2 pg/mm post-obstruction). 3. Administration of indomethacin to the unilateral post-obstructive rats slightly raised the urine osmolality of the post-obstructed kidney (from 339 ± 17 to 390 ± 22 mosmol/kg H2O), while it had a greater effect on the contralateral intact kidney (from 1569 ± 138 to 2567 ± 198 mosmol/kg H2O). 4. Our data may indicate that the urine concentration defect after 24 h ureteral occlusion is ascribable mainly to a mechanism other than increased endogenous PGE2.

Sign in / Sign up

Export Citation Format

Share Document